HugoScore hugoscore.org

Clinical trial matching AI

TrialScreen

TrialScreen offers trial search and automated prescreening. A match is not a final enrollment decision. Current policy permits some disclosures beyond express consent alone, and removal of information already sent to study teams depends on those teams.

Document-based draft Read full report Open directory

Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.

Mixed6 of 12 agency checks metDocument-based draft. Independent confirmation incomplete; not product-tested.How categories work

Agency checklist · October 30, 2026

Mixed 6 of 12 yes

Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.

Assessed function: TrialScreen public clinical trial search and automated eligibility prescreening for patients; sponsor-managed recruitment (REFER) and site enrollment decisions assessed only where they touch the patient

A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.

  • Public documents do not establish actual product behavior.
  • The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
QuestionAnswerEvidence / reviewSource and reasoning
1. Told it is AINonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Privacy says 'the eligibility checker is an automated process and the outcome is based on the information you provide and the eligibility criteria of the trial'. No public page says AI or machine learning is used. It may be rule-based; if so this question may be not applicable.

2. Operator and model maker namedNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

TrialScreen Pty Ltd and TrialScreen Inc. are named in the privacy policy contacts. No AI model or maker is named, and none is disclosed.

3. Patient chooses to use itYesdocumented
Not independently replicated
check your own fit before you share a single contact detail Source

Patient searches and chooses whether to run a check and whether to share contact details. Sponsors page: 'Sharing details isn't a requirement, it's a choice.'

4. Patient sets the taskNodocumented
Not independently replicated
TrialScreen is a clinical trial awareness and lead generation company. Source

Judgment call. Patient chooses what to search, but the operator's stated business is sponsor lead generation, paid per contactable lead, and the flow routes patients to study teams. Operator goal shapes the function.

5. Patient can decline or stopYesdocumented
Not independently replicated
check your own fit before you share a single contact detail Source

Self-started rule applied (cites question 3 source).

6. Patient sees the AI outputYesdocumented
Not independently replicated
based on your answers, you may not meet the criteria for any of your saved studies right now Source

Eligibility result is shown to the patient in the site's own UI strings (public JS asset). Also 'You may be eligible - contact the study team'. Quote is from the English string in the bundle.

7. Patient can correct or challengeNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Privacy offers access and correction of personal information held. No documented route to contest the automated eligibility result.

8. Patient can get a copyYesdocumented
Not independently replicated
You may request access to the personal information we hold about you Source

Privacy also lists a right to data portability, depending on location.

9. Patient can deleteYesdocumented
Not independently replicated
you can change your mind and ask us to remove your details Source

Applies where consent is the basis. If the patient was connected to a trial, the request is forwarded to the study team.

10. Training or sale does not override patient choiceYesdocumented
Not independently replicated
We do not sell your personal information. Source

No model training is disclosed (no AI documented). Sharing with sponsors or sites is 'only with your consent or where reasonably expected'. Pay-per-lead model is covered in question 12.

11. Patient can run it or take it elsewhereNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Vendor-hosted only.

12. No advertising or data businessNodocumented
Not independently replicated
You only pay per contactable lead, we take on the design and advertising risk. Source

Sponsors pay per lead of consenting patients. Applying the rule that data business counts even with consent. About page: 'clinical trial awareness and lead generation company'.

Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.

Checklist rules · Independent review and limitations · Later evidence follow-up

Earlier v1.3 assessment and control finding

Historical assessment under different rules. It does not set the current checklist zone.

MixedEarlier review, before the published method. Documents only.

Agency finding, before method v1.3

Mixed, open patient search funded by sponsor recruitment

Legacy editorial placement, pre-method: 55

This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.

Evidence
Documentary review. Public sources only, no hands-on testing by HugoScore.
Review status
AI draft. No person has settled the findings.
The question we ask Who does TrialScreen serve in this deployment?
Control TrialScreen public clinical trial search and automated eligibility prescreening for patients; sponsor-managed recruitment (REFER) and site enrollment decisions assessed only where they touch the patient
Agency read Mixed
Vendor
TrialScreen Pty Ltd (with TrialScreen Inc. in the US)
Who it serves
Hybrid public trial search engine operated by a sponsor-side recruitment company
Primary User
Patients, families, healthy volunteers, and physicians searching for trials; paying users are sponsors, CROs, SMOs, sites, and academic researchers
Control Model
Vendor-hosted public service. Controls and downstream processors depend on the assessed deployment.
Patient Impact
Trial discovery supports action. The reviewed public pages do not establish an explanation or appeal path for false-negative screening, so do not equate a match result with final eligibility.
Profile Status
Document-based draft
Last assessed
Oct 30, 2026
Earlier review confidence
Moderate for published screening and data terms (AI-assisted draft)
Earlier review model
OpenAI Codex / GPT-6
Earlier human review record
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Earlier evidence and assessment

The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.

Earlier finding · Legacy editorial placement, pre-method: 55

Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 55. Not comparable with v1.3 positions.

Mixed, open patient search funded by sponsor recruitment

TrialScreen offers trial search and automated prescreening. A match is not a final enrollment decision. Current policy permits some disclosures beyond express consent alone, and removal of information already sent to study teams depends on those teams.

Patient agency

How this tool changes agency

Expands agency when

Trial discovery supports action. The reviewed public pages do not establish an explanation or appeal path for false-negative screening, so do not equate a match result with final eligibility.

Limits agency when

Search ranking, sponsored labels, explanation of exclusions and patient screening-data retention remain unverified

Patient agency assessment

Who sets and changes the goal?

Patient authority

Historical no-account search gives users room to explore. Screening may narrow perceived options, so correction of input and access to researchers matter more than free access alone.

What can the patient understand, question, or do?

Critical capacity

Trial discovery supports action. The reviewed public pages do not establish an explanation or appeal path for false-negative screening, so do not equate a match result with final eligibility.

Can the patient evaluate the conditions of use?

Informed control

The baseline's consent-only sharing language is stronger than the current policy, which contains additional permitted bases. Downstream removal depends on study teams.

Text findings

Conditions of use

Published controls and their limits

The baseline's consent-only sharing language is stronger than the current policy, which contains additional permitted bases. Downstream removal depends on study teams.

What remains unknown?

Not tested or not established

Search ranking, sponsored labels, explanation of exclusions and patient screening-data retention remain unverified

Who evaluated this?

AI-assisted public-source draft

Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.

Sources checked

Source-specific findings and retrieval limitations are recorded in the full report.

Earlier review provenance

Criteria

CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.

Reviewer

AI-assisted public-source reassessment prepared in OpenAI Codex.

AI / model

OpenAI Codex / GPT-6

Human review

Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Review date

2026-09-08

Limitations

Search ranking, sponsored labels, explanation of exclusions and patient screening-data retention remain unverified No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.

Earlier review method

Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.

Document-based draft · Moderate for published screening and data terms (AI-assisted draft)